These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25604317)

  • 1. Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
    Witte T
    Clin Rheumatol; 2015 Apr; 34(4):629-34. PubMed ID: 25604317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?].
    Witte T
    Z Rheumatol; 2013 Apr; 72(3):279-86. PubMed ID: 23440377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study.
    Mueller RB; Graninger W; Sidiropoulos P; Goger C; von Kempis J
    Clin Rheumatol; 2017 Oct; 36(10):2187-2192. PubMed ID: 28776300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The issue of bioavailability of oral low dose methotrexate: should we choose only 10 mg of MTX a week in conjunction with anti-TNF therapy?
    Zeidler H
    Ann Rheum Dis; 2014 Aug; 73(8):e50. PubMed ID: 24764450
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Teitsma XM; Yang W; Jacobs JWG; Pethö-Schramm A; Borm MEA; Harms AC; Hankemeier T; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Arthritis Res Ther; 2018 Oct; 20(1):230. PubMed ID: 30322408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.
    Dhillon S
    BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage.
    Richez C; Barnetche T; Khoryati L; Duffau P; Kostine M; Contin-Bordes C; Blanco P; Schaeverbeke T
    J Rheumatol; 2012 Jun; 39(6):1192-7. PubMed ID: 22467922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab: is there life beyond anti-TNF blockade?
    Alves JD; Marinho A; Serra MJ
    Int J Clin Pract; 2011 Apr; 65(4):508-13. PubMed ID: 21272164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New biologics for rheumatoid arthritis.
    Choy E
    J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life.
    Iannone F; Notarnicola A; Lopalco G; Lapadula G
    Joint Bone Spine; 2014 Oct; 81(5):458-9. PubMed ID: 24656742
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.
    Manders SH; Kievit W; Adang E; Jansen TJ; Stolk JN; Visser H; Schilder AM; Vonkeman HE; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2015 Mar; 74(3):e24. PubMed ID: 25480886
    [No Abstract]   [Full Text] [Related]  

  • 20. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.